Arrowhead Pharmaceuticals, Inc. is a Nasdaq listed (ARWR) company that develops novel drugs to treat intractable diseases by silencing the genes that cause them.  Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (RNAi) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.  The Company's pipeline includes ARO-HBV for chronic hepatitis B virus, ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (AATD), ARO-F12 for hereditary angioedema and thromboembolic disorders, ARO-HIF2 for renal cell carcinoma, and ARO-AMG1 for an undisclosed genetically validated cardiovascular target under a license and collaboration agreement with Amgen, Inc.  ARO-LPA for cardiovascular disease was recently out-licensed to Amgen.

Arrowhead’s dynamic and innovative environment offers employees the opportunity to advance revolutionary treatments for serious and intractable diseases.  Arrowhead's employees are smart, creative professionals who work collaboratively to meet the Company's business and scientific challenges. Arrowhead’s modern and well-equipped Research & Development ("R&D") facility is located in the Research Park in Madison, Wisconsin.  The company is headquartered in Pasadena, CA.